Abhishek Prasad

Abhishek Prasad

Auto-generated profile, based on publicly available information

Abhishek Prasad

Department of Anesthesiology and PeriOperative Medicine, Duke University Medical Center, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
RDRupak Desai
Rupak Desai
APAbhishek Prasad
Abhishek Prasad
JNJai Sivanandan Nagarajan
Jai Sivanandan Nagarajan
AGAnanth Guddeti
Ananth Guddeti
NMNavya Mandalapu
Navya Mandalapu
MGMuhammad Usman Ghani
Muhammad Usman Ghani
The Anatolian Journal of Cardiology - Peer-reviewed cardiology journal publishing original research, reviews, case reports. Impact Factor 1.5. The Anatolian Journal of Cardiology - Leading international cardiology journal with Impact Factor 1.5. Publishing original research, reviews, and case reports in cardiovascular medicine. Indexed in PubMed, Scopus, and Web of Science.

17 September 2026 in Indian Journal of Anaesthesia
Verified
Journal Article
Open access
APAbhishek Prasad
Abhishek Prasad
Was not provided for this article.

23 May 2026 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
FBFnu Bhuvan
Fnu Bhuvan
APAbhishek Prasad
Abhishek Prasad
HAHasnain Ali
Hasnain Ali
GCGiorgi Chilingarashvili
Giorgi Chilingarashvili

18 June 2026 in Heart Rhythm O2
Verified
Journal Article
Open access
MGMuhammad Usman Ghani
Muhammad Usman Ghani
APAbhishek Prasad
Abhishek Prasad
JNJai Sivanandan Nagarajan
Jai Sivanandan Nagarajan
DPDarsh Tusharbhai Patel
Darsh Tusharbhai Patel
RDRupak Desai
Rupak Desai
SCSubhasis Chatterjee
Subhasis Chatterjee

6 July 2026 in BMC Cancer
Verified
Journal Article
Open access
SBShantanu Bhattacharyya
Shantanu Bhattacharyya
DTDr jitu Varghese Thomas
Dr jitu Varghese Thomas
APAbhishek Prasad
Abhishek Prasad
ADArunima Deep
Arunima Deep
FBF. N. U. Bhuvan
F. N. U. Bhuvan
RGRajesh Kumar Garanayak
Rajesh Kumar Garanayak
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression, and is associated with limited targeted treatment options and poor clinical outcomes. Although major genomic studies have characterized TNBC in Western populations, the genomic landscape of TNBC in South Asian populations remains insufficiently understood despite a relatively high disease burden in this region. We conducted a systematic review following PRISMA 2020 guidance to synthesize available genomic evidence on TNBC in South Asian cohorts. Studies reporting genomic alterations in TNBC patients from South Asia were identified through searches of PubMed, Scopus, Web of Science, and ProQuest, supplemented by citation tracking and a ClinicalTrials.gov search. Eight studies from India and Pakistan met the eligibility criteria. Because the evidence base was sparse and clinically and methodologically heterogeneous, and because the number of studies reporting extractable denominators for any single biomarker did not reach our pre-specified threshold for pooling, data were synthesized descriptively rather than by meta-analysis. Across the included studies, recurrent alterations were reported in key tumor-suppressor and DNA-repair genes, particularly BRCA1, BRCA2, and TP53. Germline BRCA1 alterations were reported at a relatively high frequency in several cohorts, most notably in Pakistani TNBC patients, suggesting a contribution of hereditary DNA-repair defects to TNBC pathogenesis in this population. These findings highlight the importance of population-specific genomic analyses and support the growing role of DNA-repair-directed therapies and biomarker-driven precision oncology strategies in TNBC management. We additionally propose, as recommendations for future work, a two-tier framework for ancestry classification and a tiered scheme for harmonizing homologous recombination deficiency (HRD) reporting.